Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 5
2011 2
2012 7
2013 16
2014 21
2015 38
2016 33
2017 39
2018 42
2019 58
2020 44
2021 65
2022 55
2023 55
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30272896 Free Books & Documents. Review.
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule with a molecular weight of 149,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the i …
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule …
Mogamulizumab.
[No authors listed] [No authors listed] 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643268 Free Books & Documents. Review.
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneous T-cell lymphomas. Mogamulizumab is associated with a low rate of serum enzyme elevations during treatment and has been linked to se …
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneou …
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included in the safety population. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival compared with vor …
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included i …
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H, Kamachi K, Kimura S. Ureshino H, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):326-331. doi: 10.1016/j.clml.2019.03.004. Epub 2019 Mar 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30981611 Review.
Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. ...It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin …
Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab …
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Moore DC, et al. Ann Pharmacother. 2020 Apr;54(4):371-379. doi: 10.1177/1060028019884863. Epub 2019 Oct 25. Ann Pharmacother. 2020. PMID: 31648540 Review.
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and administration of mogamulizumab for the treatment of T-cell lymphomas. Data Sources: A literature search of PubMed (1966 to September 2019) was conducted using the keywords mogamulizu …
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and administration of mogamulizumab for the treatm …
Mogamulizumab for the treatment of T-cell lymphoma.
Makita S, Tobinai K. Makita S, et al. Expert Opin Biol Ther. 2017 Sep;17(9):1145-1153. doi: 10.1080/14712598.2017.1347634. Epub 2017 Jul 3. Expert Opin Biol Ther. 2017. PMID: 28649848 Review.
Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Expert opinion: Mogamulizumab has potent clinical efficacy against CCR4-positive T-cell lymphomas, especially against ATL. Among various t …
Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Exper …
Mechanisms of resistance to mogamulizumab.
Querfeld C. Querfeld C. Blood. 2022 Jun 30;139(26):3674-3676. doi: 10.1182/blood.2022016594. Blood. 2022. PMID: 35771561 Free article. No abstract available.
Mogamulizumab in the treatment of advanced mycosis fungoides and Sezary syndrome: safety and efficacy.
Lewis DJ, Rook AH. Lewis DJ, et al. Expert Rev Anticancer Ther. 2020 Jun;20(6):447-452. doi: 10.1080/14737140.2020.1760096. Epub 2020 Apr 28. Expert Rev Anticancer Ther. 2020. PMID: 32320304 Review.
AREAS COVERED: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. ...Since it eliminates malignant T cells via ADCC, combining mogamulizumab with immunotherapeutic agents such as interferons, interleukin-12, a …
AREAS COVERED: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. ...Since i …
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA, Sahin I, Olszewski AJ. Ollila TA, et al. Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019. Onco Targets Ther. 2019. PMID: 30799938 Free PMC article. Review.
Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogamulizumab may result in severe or refractory graft vs host disease after allogeneic bone marrow transplantation, highlighting the need fo …
Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogam …
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM, Rieger KE, Bagot M, Choi JN, Fisher DC, Guitart J, Haun PL, Horwitz SM, Huen AO, Kwong BY, Lacouture ME, Noor SJ, Rook AH, Seminario-Vidal L, Vermeer MH, Kim YH. Musiek ACM, et al. Dermatol Ther (Heidelb). 2022 Jan;12(1):29-40. doi: 10.1007/s13555-021-00624-7. Epub 2021 Nov 23. Dermatol Ther (Heidelb). 2022. PMID: 34816383 Free PMC article. Review.
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS). One of the most comm …
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall res …
428 results

Searches related to "mogamulizumab"